March 27, 2018 / 11:54 AM / a month ago

Esperion's cholesterol drug succeeds in mid-stage study

March 27 (Reuters) - Esperion Therapeutics Inc said on Tuesday a mid-stage study of its experimental oral drug met the main goal of reducing cholesterol.

Esperion’s 8-week study tested a 180 mg per day dose of its drug, bempedoic acid, versus a placebo in 58 patients with high cholesterol.

Shares of the company were up 2.17 percent at $73.35 in premarket trading. (Reporting by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below